treatment landscape

Articles tagged with “treatment landscape”

1 article

AXS-05 Nears FDA Decision for Alzheimer's Agitation

AXS-05, an oral NMDA-targeting drug, nears FDA approval for Alzheimer's agitation. Here's what it means for the ketamine treatment landscape.

Have a correction, provider question, or advertising inquiry? Reach the editorial team.